2025-05-04 - Analysis Report
## Recursion Pharmaceuticals Inc. (RXRX) Stock Review

**0) Key Figures & Initial Analysis:**

RXRX, Recursion Pharmaceuticals Inc., is a biotechnology company using AI to discover and develop new drugs.  The company shows significant underperformance compared to the S&P 500.

**1) Performance Comparison:**

* **RXRX Cumulative Return:** -46.88%
* **VOO (S&P 500) Cumulative Return:** 19.97%
* **Return Difference:** -66.9% (RXRX underperformed VOO by 66.9 percentage points).
* **Relative Divergence:** -66.9% places RXRX at the 6.1 percentile of its historical range relative to VOO, indicating substantial underperformance.


**Alpha/Beta Analysis:**

The provided alpha/beta analysis shows consistently negative alpha and high beta values across the analyzed periods (2021-2025).  This suggests RXRX significantly underperformed the market (negative alpha) and exhibited high volatility (high beta). The high Maximum Drawdown (MDD) further confirms this high risk profile.  The shrinking market capitalization also signals a potential decrease in investor confidence.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2021-2023  | 5.0% | 73.6% | -12.0% | 4.0   |
| 2022-2024  | 0.0% | 73.6% | -22.0% | 2.8   |
| 2023-2025  | 5.0% | 73.6% | -14.0% | 2.3   |


**2) Recent Price Movement:**

* **Closing Price:** $5.70
* **Last Market Change:** +3.64% (a notable daily increase)
* **5-Day Moving Average:** $5.67
* **20-Day Moving Average:** $5.29
* **60-Day Moving Average:** $6.55

The price is currently trading below all three moving averages, suggesting a bearish trend. The recent positive daily change (+3.64%) might be a short-term fluctuation.


**3) Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.3776 (Medium Risk)
* **RSI:** 48.56 (Near neutral; neither overbought nor oversold)
* **PPO:** 1.62 (Positive, suggesting potential upward momentum, although the overall trend is bearish)
* **20-Day Relative Divergence Change:** -2.3% (Short-term downward trend)
* **Expected Return:** -565.3%  This extremely negative expected return, relative to the S&P 500, further emphasizes significant underperformance and high risk.  A long-term (2+ years) investment strategy in RXRX would require a very high risk tolerance given its current trajectory.  The recent price increase (3.64%) is a short-term event and does not alter this long-term outlook.


**4) Recent Earnings Analysis:**

The company consistently reports negative EPS and low revenue.  While revenue showed a slight increase in Q3 2024, overall financial performance is weak.


| Date       | EPS    | Revenue    |
|------------|--------|------------|
| 2024-11-06 | -$0.34 | $0.03 B    |
| 2024-08-08 | -$0.40 | $0.01 B    |
| 2024-05-09 | -$0.39 | $0.01 B    |
| 2023-11-09 | -$0.43 | $0.01 B    |
| 2024-11-06 | -$0.43 | $0.01 B    |


**5) Financial Information:**

The financial statements reveal significant issues with profitability and return on equity (ROE).  Negative profit margins and negative ROE across multiple quarters indicate substantial financial distress.  The large swing in profit margin between Q3 and Q4 2024 needs further investigation.


**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2024-12-31 | $0.00B   | -183.62%      |
| 2024-09-30 | $0.03B   | 53.69%        |
| 2024-06-30 | $0.01B   | 36.14%        |
| 2024-03-31 | $0.01B   | 17.23%        |
| 2023-12-31 | $0.01B   | 6.99%         |


**Capital and Profitability:**

| Quarter    | Equity   | ROE          |
|------------|----------|--------------|
| 2024-12-31 | $1.03B   | -17.29%       |
| 2024-09-30 | $0.52B   | -18.27%       |
| 2024-06-30 | $0.58B   | -16.69%       |
| 2024-03-31 | $0.40B   | -22.78%       |
| 2023-12-31 | $0.46B   | -20.07%       |


**6) Overall Conclusion:**

Recursion Pharmaceuticals (RXRX) shows extremely poor performance relative to the S&P 500, with significant negative alpha and high beta.  The company is facing substantial financial challenges, reflected in negative profit margins, negative ROE, and consistently negative EPS. While recent price movements show some short-term fluctuations, the long-term outlook is extremely bearish.  Investing in RXRX requires a very high tolerance for risk.  Further investigation into the reasons for the extreme negative profit margin in Q4 2024 and the overall financial health of the company is crucial before any investment decision.
